Skip to content

Immunotherapies

JDRF is striving to accomplish a feat that has never been achieved before: permanently turning off an autoimmune response in humans. The JDRF Immunotherapy Program aims to turn off the deadly attack against beta cells that causes type 1 diabetes (T1D). We power groundbreaking research and development of new therapies that will stop the autoimmune attack at its earliest stages.

Our Approach

Our immune systems protect us against threats from within and without. In people with T1D, the immune system mistakes the body’s own cells for dangerous invaders and targets the pancreas’ insulin-producing beta cells. As a result of beta cell death, people with T1D depend on external insulin to survive.

  • Disable overactive immune assassins

    so progression to T1D never happens

  • Boost “good” cells

    that can control and inhibit killer cells

  • Restore the environment

    for continued immune control against beta cells

“Living with the burden of T1D is far from easy. It can bring you to your knees. But after being involved in an immunotherapy research trial and seeing the results first hand, I know a cure is possible. JDRF is going to make it happen.”

Jake F.

18 years old, diagnosed at age 16

Jake F.

Many Paths, One Purpose

Our research into immunotherapy technologies is just one potential pathway to finding a cure. Explore JDRF’s ambitious research portfolio.

All Research

Looking Ahead

To date, more than $145 million has been invested by JDRF on immunotherapy research. We are striving to accomplish a feat that has never been achieved before: permanently turning off an autoimmune response in humans.

We Need Advocates Like You!

Advocate for a multi-year renewal of the Special Diabetes Program which provides $150 mil annually toward T1D research.

Join Today